Home › Pulmonary Arterial Hypertension › New York › New York City
Pulmonary Arterial Hypertension clinical trials in New York City, NY
5 studies for Pulmonary Arterial Hypertension are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
RecruitingPhase 3
- NYU Langone Health, New York
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
RecruitingPhase 3
- NYU Langone Health, New York
Pulmonary Hypertension Association Registry
RecruitingObservational study
- Weill Cornell Medical Center, New York
- Columbia University Medical Center/NewYork-Presbyterian Hospital, New York
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
Recruiting
- Cornell University, New York
- University of Rochester, New York
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
RecruitingObservational study
- Columbia University Medical Center, New York
- Maria Fareri Children's Hospital at WMC Health/Westchester Medical Center, New York
Pulmonary Arterial Hypertension trials in other cities
- Durham, NC7 studies
- Mountain View, CA7 studies
- Cincinnati, OH7 studies
- Kansas City, KS7 studies
- Boston, MA7 studies
- Aurora, CO7 studies
- Nashville, TN7 studies
- Philadelphia, PA6 studies
- Seattle, WA5 studies
- Louisville, KY4 studies
- Los Angeles, CA4 studies
- Dallas, TX4 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.